Symptoms and Quality of Life in Gastroenteropancreatic Neuroendocrine Tumours

European Medical Journal Oncology

article

Sebastian Kaupp-Roberts¹  Rajaventhan Srirajaskanthan²  John K. Ramage¹ 

[1]Department of Gastroenterology and Hepatology, Hampshire Hospitals  NHS Foundation Trust

[2]Neuroendocrine Tumour Service, Institute of Liver Studies, King’s College Hospital

关键词: Quality of life;    patient-reported outcome measures (PROMs);    gastroenteropancreatic neuroendocrine tumours (GEP-NETs);    symptoms;    GINET21;    QLQ-C30;    syndromes;    neuroendocrine tumours (NETs).;   

DOI  :  10.33590/emjoncol/10313153

学科分类：社会科学、人文和艺术（综合）

来源: European Medical Journal

【 摘 要 】

Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have the ability to induce symptoms either by their direct mass effect on local tissues (symptoms such as pain, bowel obstruction, obstructive  jaundice, and bleeding), or by the ectopic secretion of bioactive compounds. GEP-NETs are frequently associated with significant diagnostic delays, and metastatic disease is often a feature at initial  presentation. Quality of life (QoL) research in GEP-NETs is a comparatively new field, with a disease- specific QoL questionnaire, the QLQ-GINET21, having been fully validated only as recently as 2013. It has been reliably demonstrated to date that diarrhoea, fatigue, and flushing are the symptoms provoking  the greatest decline in patient QoL. Furthermore, depression is highly prevalent in the GEP-NET  population. This paper reviews current understanding and potential future developments in this field.

【 授权许可】

CC BY-NC